Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 111

Results For "FDA"

1720 News Found

Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows achieved groundbreaking results in liver disease due to MASH
Diagnostic Center | February 28, 2024

Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows achieved groundbreaking results in liver disease due to MASH

Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis


Briefs: Suven Pharmaceuticals, Remedium Lifecare and Kilitch Drugs India
News | February 24, 2024

Briefs: Suven Pharmaceuticals, Remedium Lifecare and Kilitch Drugs India

Suven Pharmaceuticals’ API and forumulations facilities complete USFDA inspection successfully


Moderna posts Q4 2023 revenue at US$ 2.8 billion
News | February 23, 2024

Moderna posts Q4 2023 revenue at US$ 2.8 billion

Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance


Briefs: IOL Chemicals and Pharmaceuticals and Auro Peptides
News | February 20, 2024

Briefs: IOL Chemicals and Pharmaceuticals and Auro Peptides

IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China


Blacksmith Medicines and Zoetis collaborate for novel animal health antibiotics
News | February 17, 2024

Blacksmith Medicines and Zoetis collaborate for novel animal health antibiotics

Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock


Lupin launches Ganirelix Acetate Injection in US
News | February 16, 2024

Lupin launches Ganirelix Acetate Injection in US

It is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation


Lupin launches Bromfenac Ophthalmic Solution, 0.075% in US
News | February 14, 2024

Lupin launches Bromfenac Ophthalmic Solution, 0.075% in US

Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.


MIRA Pharmaceuticals announces collaboration with Pharmaseed
News | February 08, 2024

MIRA Pharmaceuticals announces collaboration with Pharmaseed

Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024


Glenmark partners Pfizer to launch Abrocitinib in India
Drug Approval | February 01, 2024

Glenmark partners Pfizer to launch Abrocitinib in India

Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India